Speaker(s): 

Christopher Capelli, MD, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

Mark Karcutskie, MD, Staff Member, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

  • Explain the changes in metabolism of non-depolarizing muscle relaxants in renal failure.
  • Discuss the risks vs benefits of rocuronium and sugammadex use in patients with end stage renal disease.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Matthew Desciak, MD, Mark Karcutskie, MD, William Cooper, CRNA, Lorraine Kuchta, and Colleen Lear have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.

Session date: 
03/04/2026 - 6:45am to 7:45am EST
Location: 
GWV Anesthesia Classroom and Virtual via Microsoft Teams
Wilkes-Barre, PA
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation Credit
Please login or register to take this course.